The Norwegian Research Council recently granted funding to Oslo Cancer Cluster members; BerGenBio, Bionor Immuno, GE Healthcare, Lytix Biopharma, PCI Biotech, Zelluna and Phoenix Solutions through the Programme for User-Driven Research Based Innovation (BIA).
In total, the Research Council will grant 406 MNOK to 42 Norwegian companies in this application round. A total of 187 applications was filed.
Overview of member companies and their funded projects:
- Bionor Immuno is granted MNOK 10.3 to further advance Vacc-4x in a combination treatment regimen
- BerGen Bio is granted funding to a project on leveraging Investigator-Initiated Trials to develop novel treatment options for AXL driven cancers with high unmet clinical need 
- GE Healthcare is granted funding to a project on a new paradigm within MRI: development of a novel manganese based contrast agent with high commercial value
- Lytix Biopharma is granted NOK 15.9 million to support the investigation of LTX-315’s ability to make ’’cold tumors hot’’ and Phase II trial in Triple Negative Breast cancer (TNBC) 
- PCI Biotech is granted NOK 13.8 million to the project “Photochemical vaccination – novel immunotherapy concept for treatment of cancer and infectious diseases” 
- Phoenix Solutions is granted NOK 15.8 million from the Research Council of Norway to the project “ACT for Pancreatic Cancer” 
- Zelluna, named as TCR Biopharma:Development of T-cell based cancer therapy
Funding from the BIA programme is a quality stamp since the companies compete in “open class” where all sectors are represented. On the Research Council`s website you may find the total list of all the 42 companies  (in Norwegian) and read more about the funding from the BIA-programme.